<DOC>
	<DOCNO>NCT03001076</DOCNO>
	<brief_summary>The purpose study determine bempedoic acid ( ETC-1002 ) added-on ezetimibe therapy effective safe versus placebo patient elevate LDL cholesterol .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Bempedoic Acid ( ETC-1002 ) Add-on Ezetimibe Therapy Patients With Elevated LDL-C ( CLEAR Tranquility )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Fasting LDLcholesterol great equal 100 mg/dL screen Men nonpregnant , nonlactating woman Use stable lipidmodifying therapy least 4 week prior screen include ezetimibe 10mg daily Fasting blood triglyceride great equal 500 mg/dL Body Mass Index ( BMI ) great equal 50 kg/m2 Recent history clinically significant cardiovascular disease Use statin therapy dose great define `` lowdose '' within 4 week prior screen ; `` lowdose '' define average daily dose rosuvastatin 5 mg , atorvastatin 10 mg , simvastatin 10 mg , lovastatin 20 mg , pravastatin 40 mg , fluvastatin 40 mg , pitavastatin 2 mg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hyperlididemia</keyword>
	<keyword>LDL</keyword>
	<keyword>cholesterol</keyword>
	<keyword>statin intolerance</keyword>
</DOC>